title: Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.
abstract: OBJECTIVE
  This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan.
  
  
  METHODS
  All the consensus contents were voted on by the participating experts, with approval by no less than 75% required for inclusion.
  
  
  RESULTS
  The consensus provides a comprehensive overview of EGFR-TKI skin toxicities, including recent advances in identifying their causes and the processes by which they develop.
  
  
  CONCLUSIONS
  All the consensus meeting attendees agreed that there are several major EGFR-TKI-related skin toxicities, including acneiform rash (i.e., papulopustular rash), xeroderma, pruritus, paronychia, stomatitis, mucositis, and hair changes (such as hair loss, slowed hair growth, and trichomegaly). The experts were also generally unanimous in their voting on the specific definitions, onset times, and care suggestions for each of those skin toxicities. Furthermore, the recommended treatment algorithms for the various skin toxicities were ultimately approved by 100% (15/15) of the consensus attendees.
authors.affiliation: Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: chiayu@ntu.edu.tw.
authors.forename: Chia-Yu
authors.initials: CY
authors.lastname: Chu
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Kuan-Yu
authors.initials: KY
authors.lastname: Chen
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
authors.forename: John
authors.initials: J
authors.lastname: Wen-Cheng Chang
authors.affiliation: Department of Internal Medicine, I-Shou University and E-Da Hospital, Kaohsiung, Taiwan.
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Wei
authors.affiliation: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan, Taiwan.
authors.forename: Chih-Hung
authors.initials: CH
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.
authors.forename: Wei-Ming
authors.initials: WM
authors.lastname: Wang
mesh_terms: D003875:Drug Eruptions / Q000175:diagnosis* / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D012955:Societies, Medical; D013624:Taiwan
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
keywords: consensus; diagnosis; epidermal growth factor receptor; skin toxicities; tyrosine kinase inhibitors